.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01C_PlantAlkaloidsAndOtherNaturalProducts.L01CA05_Vinflunine.Vinflunine .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01C_PlantAlkaloidsAndOtherNaturalProducts.L01CA05_Vinflunine.Vinflunine| name: | Vinflunine |
| ATC code: | L01CA05 | route: | intravenous |
| n-compartments | 3 |
Vinflunine is a synthetic microtubule inhibitor of the vinca alkaloid family used as a chemotherapeutic agent. It is approved for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract after failure of platinum-containing therapy, particularly in Europe.
Pharmacokinetics reported in adult cancer patients after a single intravenous infusion of vinflunine at 320 mg/m2 over 20 minutes.
Frampton, JE, & Moen, MD (2010). Vinflunine. Drugs 70(10) 1283–1293. DOI:10.2165/11204970-000000000-00000 PUBMED:https://pubmed.ncbi.nlm.nih.gov/20568834
Schmitt, A, et al., & Pétain, A (2018). Better characterization of vinflunine pharmacokinetics variability and exposure/toxicity relationship to improve its use: Analyses from 18 trials. British journal of clinical pharmacology 84(5) 900–910. DOI:10.1111/bcp.13518 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29341179
Souquet, PJ, et al., & Rosell, R (2010). Phase I/II and pharmacokinetic study of intravenous vinflunine in combination with cisplatin for the treatment of chemonaive patients with advanced non-small-cell lung cancer. Clinical lung cancer 11(2) 105–113. DOI:10.3816/CLC.2010.n.014 PUBMED:https://pubmed.ncbi.nlm.nih.gov/20199976